Clinical trial
Safety and Efficacy Study of I-131 Tositumomab in Patients With…
NCT00484874 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00484874 |
|---|---|
| Title | Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma |
| Official title | A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin's Disease |
| Intervention type | Drug |
| Interventions | I-131 Tositumomab therapeutic regimen |
| Enrollment | 12 |
| Start date | Jun 1, 2007 |
| Primary completion | Jan 1, 2014 |
| Completion | Nov 1, 2015 |
| First posted | Jun 11, 2007 |
| Last update posted | Aug 1, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: